Minerva Neurosciences IncNASDAQ:NERVNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE2.4900
- TODAY'S CHANGE (%)-0.0400 (-1.5810%)
- Bid / Lots2.4900/ 1
- Ask / Lots2.5500/ 1
- Open / Previous Close2.5300 / 2.5300
- Day Range
- 52 Week Range
- Volume2,454
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NERV |
|---|---|---|
| 09:32 ET | 230 | 2.53 |
| 10:21 ET | 1755 | 2.49 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Minerva Neurosciences Inc | 17.7M | -0.5x | --- |
CytoMed Therapeutics Ltd | 24.8M | -5.6x | --- |
Raphael Pharmaceutical Inc | 18.7M | -12.5x | --- |
Aptose Biosciences Inc | 18.9M | -0.2x | --- |
Galecto Inc | 19.0M | -0.5x | --- |
Biomx Inc | 19.1M | -0.6x | --- |
Company Information
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. It is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). Roluperidone is a compound that blocks serotonin, sigma, and a-adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders.
Contact Information
- Headquarters
- 1601 TRAPELO ROAD, SUITE 284WALTHAM, MA, United States 02451
- Phone
- 617-600-7373
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board of Directors, Chief Executive Officer
- Remy Luthringer
- President
- Geoffrey Race
- Chief Financial Officer, Senior Vice President, Secretary
- Frederick Ahlholm
- Chief Operating Officer, Senior Vice President
- Joseph Reilly
- Senior Vice President, Head of Research and Development
- Ramana Kuchibhatla
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $17.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 7.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.24 |
EPS | $-4.65 |
Book Value | $-4.07 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
